A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia.

The problematic treatment of infections caused by multiple-resistant Klebsiella, especially in ICU, is the leading cause of prolonged hospitalization and high mortality rates. The use of antibiotics for the prevention of infections is considered unreasonable as it may contribute to the selection of resistant bacteria. In this regard, the development of drugs that will be effective in preventing infection during various invasive procedures is extremely necessary. We have shown that the developed innovative antibacterial compound fluorothiazinone (FT) that suppresses the formation of biofilms is effective in the prevention of a model pneumonia caused by a multi-resistant clinical K. pneumoniae isolate. Prophylactic use followed by treatment with FT in mice with acute pneumonia modulates the local innate immune response without suppressing protective properties in the early stages of infection, while contributing to a decrease in the bacterial load in the organs and preventing lethal pathological changes in the lungs at later stages of K. pneumoniae infection. Further development of such antivirulence drugs and their use will reduce morbidity and mortality in nosocomial infections, as well as reduce the number of antibiotics used.

[Comprehensive treatment of a child with an extensive composite odontoma]. / Kompleksnoe lechenie rebenka s obshirnoi sostavnoi odontomoi.

Odontoma make up about 22% of all odontogenic tumors. Diagnosis and treatment of odontoma in children has a number of features: the variability of the clinical and X-ray picture, the appearance of signs during the period of changing teeth, retention or the difficulty of the eruption of complete teeth in the affected area. In the process of growth odontoma can cause significant deformation of the jaw bones. The delay of the change of deciduous teeth can also be regarded as a risk factor for the formation of deviations from the normal formation of the dental system in children. This article analyzes the symptoms, clinical picture and complex treatment of a 13-year-old patient with this pathology. A clinical case demonstrates the need for regular check-ups at a pediatric dentist, an x-ray examination of the jaws in order to timely detect abnormalities in the development of the dentition of the child, diagnosis and treatment of malformations and tumors in children.

[Bright prospects and deplorable state of prolonged home mechanical ventilation in Russia: two cases' description].

The report describes two patients with lateral amyotrophic sclerosis complicated by respiratory insufficiency. Instead of long-term hospitalization to ICU the patients were kept at home, where prolonged mechanical ventilation was applied to them: in the first case - through tracheostomy tube, in the second - through mask. The use of prolonged home mechanical ventilation therapy instead of long-term hospitalization to ICU is discussed.

[Fibronectin level of the blood plasma of patients with congenital heart defects]. / Uroven' fibronektina v plazme krovi bol'nykh vrozhdennymi porokami serdtsa.

Enzyme immunoassays have shown mean fibronectin (FN) level to be 241.0 +/- 15.1 micrograms/ml in normal children between 2 and 15 years of age. Similar assays in 57 patients with congenital heart diseases (CHD) before and after surgery demonstrated preoperative FN decrease in 56% of patients, that was directly related to the extent of hemodynamic disorders, while postoperative FN level depended on the range and type of surgical trauma and the presence of inflammatory or suppurative-septic complications. Within 3 postoperative days, FN drops below normal level in 95% of patients. In spite of therapeutic use of blood and blood components, FN deficiency was not compensated for until day 10 after surgical correction of the valvular defect.

[Quantitative immunoenzyme determination of fibronectin in biological fluids]. / Kolichestvennoe immunofermentnoe opredelenie fibronektina v biologicheskikh zhidkostiakh.

Quantitative immunoenzyme assay of fibronectin in blood plasma is developed. Isolation and purification of fibronectin from human blood plasma, harvesting of specific antibodies to fibronectin, production of the antibodies and peroxidase conjugates and step-by-step procedure of the immunoenzyme assay in a "sandwich" modification are described. The assay was applied for diagnostics of several infectious and somatic diseases.

[Plasma fibronectin level in newborn infants with suppurative inflammatory diseases]. / Soderzhanie plazmennogo fibronektina u novorozhdennykh detei s gnoino-vospalitel'nymi zabolevaniiami.

The level of plasma fibronectin was determined in healthy newborns (45 plasma samples were examined in the control group) and in newborns with pyo-septic diseases (67 plasma samples were examined) by the immunoenzyme method (on the basis of the "sandwich" modification of the immunoenzyme analysis). Noticeable hypofibrinectinemia was observed in the infants with pyo-inflammatory diseases, particularly in cases of generalized forms. Combined modality etiopathogenetic therapy including i.v. plasma transfusion, did not exceed fibronectin deficiency in clinical convalescence of infants. Fibronectin deficiency is regarded as a risk factor of the development and generalization of pyo-inflammatory diseases.